QleanAir

The agreement covers the design of a USP 797/800 compliant cleanroom for pharmacy compounding within a hospital facility. The project marks the customer’s first engagement with QleanAir, and the design is expected to be completed by the end of the third quarter of 2026.

"This agreement represents another important step in QleanAir's continued expansion within the U.S. healthcare market," said Amanda Myers, Chief Commercial Officer, QleanAir Scandinavia Inc. "Leading healthcare organizations are increasingly recognizing the value of engaging experienced cleanroom specialists early in the planning process to optimize workflows, reduce project risk, and deliver long-term value."

The design agreement reflects the growing demand for strategic cleanroom planning that balances compliance, operational efficiency, and speed to implementation. By partnering with healthcare providers during the earliest stages of project development, QleanAir helps establish a strong foundation for successful project execution.

"We appreciate the trust our customer has placed in our team and look forward to delivering a design that supports their mission of providing exceptional patient care," added Zachary Douglas, President, QleanAir Scandinavia Inc.